21st.BIO

What's the advantage of working with us, you wonder? Hear the answer directly from our co-founder and CSO, Per Falholt.   "The advantage for our customers is that we can do this 10 times faster than they can, and to a better result. Because they don't have access to really high-producing strains… We've seen it 3-4x this autumn: we've gone from gene bank multiple gram of products to the customers so they can test their application in less than 6 months."   Per, our co-founder and CSO, has decades of experience in biotechnology and biomanufacturing. Per witnessed and participated in the early scientific breakthroughs in bioengineering, bringing recombinant insulin to market while at Novo Nordisk, and later heading Novozymes (now Novonesis) as CSO.   Over his career, Per has helped develop and deliver 200+ products to market. In 2021, he founded 21st.BIO together with Thomas G. Schmidt. We develop the most advanced precision fermentation technology, so our customers can safely scale their innovations and take them to market as fast and cost-effectively as possible.   Want to speed up your innovation? Let's talk ✨   #Biotech #PrecisionFermentation #Biosolutions

Move over Spider-Man, this spider #silk is recyclable, #biodegradable and stronger than steel. AMSilk GmbH | Biotech Materials CEO Ulrich Scherbel explains how the process of ‘bio-fermentation’ creates a versatile silk with many uses. AMSilk is part of the World Economic Forum’s Bioeconomy Initiative, a global community working to advance #biotech #innovations. Learn more: https://ow.ly/TZFU50V7EVm 21st.BIO #SpiderSilk #Bioeconomy #Sustainability

Scaling biotech innovations takes more than great science: it takes great partnerships.   This week, we’re delighted to host our partners from AMSilk GmbH | Biotech Materials at our Davis R&D site. Together, we’re making industrial-scale spider silk a reality. Our collaboration has already enabled the world’s first extracellular expression of spider silk proteins and is on the way to unlocking a broad market for spider silk applications 🕸️   Bringing novel biomaterials to market isn’t just about technical breakthroughs. It’s about scaling efficiently, reducing risk, and making innovation commercially viable. That’s why strong partnerships in biotech are essential – they accelerate time to market while optimizing costs and reliability. This week we have brought our teams together to ideate, prioritize and plan the development and optimization work for the coming year.   With its unmatched strength, flexibility, and biocompatibility, biosilk is redefining materials science. From biomedical applications to textiles, composites, and beyond, AMSilk GmbH | Biotech Materials is leading the way. We’re so proud to apply our strain platform in helping AMSilk get to industrial-scale production. #Biotech #Biomaterials #PrecisionFermentation

Today is the International Day of Women and Girls in Science. But honestly? At 21st.BIO, we don’t need a special day to celebrate women in STEM – it’s just the way things are. Our team is made up of incredible scientists, leaders, and innovators – women and men – who are pushing the boundaries of precision fermentation every day. Science isn’t about gender. It’s about curiosity, progress, and solving real challenges together. And that’s exactly what our team does every day, regardless of who’s in the lab, operating our pilot, or leading the next big breakthrough. Of course, representation matters. But the real goal? A world where seeing women in science isn’t exceptional – it’s just normal. #WomenInScience #STEM

What a week! From one high-level meeting to the next, the focus has been on accelerating approvals for precision-fermented proteins in the EU. That's the only way forward if we want to attract companies to establish large-scale bioproduction in Europe.   On Wednesday, we had the honor of welcoming Marie Bjerre, Danish Minister of European Affairs, and her colleagues, alongside Sofie Carsten Nielsen and Mikael Wraae Valsted from DI Biosolutions.   Our founder and CEO Thomas G. Schmidt guided the delegation through our pilot facility, showcasing: ▶️ The history and importance of precision fermentation for the Danish economy – based on the Novo legacy, ▶️ The potential of precision fermentation to nourish the world with high-quality proteins – simply copying what the cows produce,  ▶️ The need to speed up approval processes in the EU, and to directly support companies ambitioning to establish bioproduction in Europe.   And then yesterday, we attended the fantastic State of Bio, contributing actively to the establishment of DI Biosolutions by having our colleague Barbara Taudorf Andersen become a founding member of their Board of Directors – a reflection of our commitment to making Denmark and Europe the leading hub for biosolutions globally.   Across both meetings, our key messages were clear: 📈 At 21st.BIO, we are proud to develop world-leading production technology for proteins based on a legacy of Danish precision fermentation leadership – and bring it to the world. 🌍 But there’s a global race between the US, Europe, the Middle East, and Asia, to attract the companies who will invest in setting up industrial bioproduction – and Europe is falling behind. ⛔ Without faster approvals, there’s no clear path to market. If companies can’t be certain that their products will be approved in the EU within a foreseeable timeframe, they won’t even consider Europe for production – even when the technology is developed here.   This is why the EU Biotech Act must include fast-track approval for proteins made with precision fermentation. The microorganisms we use have a long, proven track record of safety, already producing many products on the market today. Europe has some of the best scientific institutions and leading industrial players in the world. It would be a shame to see the next generation of biotech leaders established only in the US, the Middle East, or China.   #Biosolutions #EU #Biotech

Repeated success is no coincidence. In the last months, we have onboarded three new customers – each working on different proteins for different industries. And three times, our expression systems delivered over 5 g/L in the supernatant within record time in phase 1B. For the untrained eye, 5 g/L may not sound like a breakthrough. But hitting it in no time? That’s rare. Biology demands hard work – and yes, sometimes a bit of luck. But when success keeps repeating, it's a sign of precision, not probability. Ready to see how fast we can reach your targets? Let's find out. #Biotech #Biosolutions #PrecisionFermentation

Under two years to take our BLG essential+™ from strain engineering to U.S. regulatory approval? Yes, that's FAST.   Curious to hear how we achieved it, and how we see precision fermentation transforming the entire dairy industry? Join José Arnau, our Executive Director, Strain Development and Regulatory Affairs, as he shares learnings and insights at this upcoming webinar.   🗓️ Mark your calendars: January 22, 2025 | 9:00-10:00 AM ET | 3:00-4:00 PM CET   Sign up for free: https://lnkd.in/dP6hwJQM   Thanks to Food Nation Denmark and The Trade Council of Denmark in North America - Energy and Environment for the invitation.

In the Chinese zodiac, 2025 will be the Year of the Snake. But at 21st.BIO, we'll celebrate it as Year of Biomanufacturing. And what better way to begin it than to welcome Niels Banke as Senior Director of Biomanufacturing. Niels brings extensive experience in biomanufacturing, having worked for Novo Nordisk, Novozymes, and more recently serving as CSO for Glycom (dsm-firmenich). As an inspiring and highly accomplished leader and scientist in fermentation, we're thrilled to have Niels leading our Fermentation and Pilot Plant teams. As we advance our technology, we continue to upscale production to industrially relevant volumes. A bottleneck for many biotech companies, industrial production is a validation that our microbial strains deliver consistent, high-quality results – at scale. We are confident that Niels will contribute to this. Welcome to the team, Niels! Here's to a fantastic year ahead for the industry.   #Biomanufacturing #Biosolutions #PrecisionFermentation

European biotechnology leadership and innovation are under pressure. For Europe to remain a hub for innovation and production, we need accelerated regulatory processes and consistent support frameworks – factors currently driving business growth across the Atlantic. This was the key message from our co-founder and CEO, Thomas G. Schmidt, in the news this morning on TV 2 Danmark. As a business leader in the field of biosolutions, Thomas was interviewed to share his insights and recommendations. At 21st.BIO, we offer world-leading production technology to make proteins for nutrition widely and readily available. Yet, our customers are increasingly incentivized to establish production in the US rather than Europe due to faster regulatory approvals, relatively more attractive operating costs and more stable support schemes. We hope that both the EU and national governments in Europe will make this a top priority, especially during the upcoming Danish EU Presidency. Access TV2's article: https://lnkd.in/dm3JZ24b